Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

Alcon

Status and phase

Completed

Phase 4

Conditions

Glaucoma

Treatments

Drug: Travoprost 0.004% Ophthalmic Solution (Travatan)

Drug: Timolol 0.5% Ophthalmic Solution (Timoptic)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00763061

MS-06-02

Details and patient eligibility

About

To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

Full description

To evaluate the IOP lowering efficacy and safety fo Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

Enrollment

111 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥18 years;
IOP=16-30mmHg
OH or OAG with visual filed abnormality:
1. ≥3 adjacent points in 24 degrees field on the same side of the horizontal meridian, that have p <5% on the prepapillary diameter plot, one of which must have p <1%,
2. Glaucoma Hemifield Test outside normal limits,
3. Corrected Pattern Standard Deviation with p <5%

Exclusion criteria

Previous damage of anterior chamber angle;
ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual Acuity (logMAR) <1.0;
contact lens wearer;
severe central field loss;
uncontrolled cardiovascular, hepatic or renal disease;
any medication within past 1 month.